We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Pascal Soriot criticises pricing agreement with UK health service
UK biotech racing to keep antibody up to date with latest variants
Sector shows signs of being under-appreciated after an anaemic year
Agreement is one of several announced as major healthcare conference begins in San Francisco
Daiichi Sankyo and AstraZeneca’s Enhertu could double time patients can live without their condition progressing
Plan abandoned almost two years after initial approval in UK and Europe
Setback for a method hoped to provide better protection against virus transmission
Drugmaker sued its former head of investor relations over alleged breach of a non-compete clause
Pharma group alleges breach of non-compete agreement to delay start date of departing business development official
Anglo-Swedish pharmaceutical group wants to capitalise on its $39bn acquisition of Alexion
Chief executive says revenue rise will allow drugmaker to boost investment in R&D
The latest strains have spread fast and governments are trying to catch up
New three-year contract in place if UK drugmaker continues to manufacture the jab
Government seeks to secure domestic jab supply and prepare for future pandemics in deal with Boston biotech
Doctors hopeful antibody therapy could change treatment for most common type of late-stage breast cancer
Revenue rises 60% as Alexion acquisition and its rare diseases medicines boost drugmaker’s earnings
Shares slide as London-listed group announces ‘pause’ in vaccine manufacturing
New therapies replace a blunderbuss with a stiletto
UK drugmaker’s R&D chief says abandoning market would have little impact
UK pharmaceuticals group raises dividend for first time in a decade
Asset managers call for pharma executive pay to be linked to equitable distribution of jabs
The apparent efficacy of its booster against Omicron could shore up the jab’s shaky position among competitors
Pharma group says it is confident its Covid vaccine ‘should be given as a third dose booster’
Global health authorities have voiced concern that current jabs may afford less protection against variant
Protection against severe disease begins to wane three months after second shot
International Edition
